HRP20201156T1 - Zajednički laki lanci i postupci primjene - Google Patents

Zajednički laki lanci i postupci primjene Download PDF

Info

Publication number
HRP20201156T1
HRP20201156T1 HRP20201156TT HRP20201156T HRP20201156T1 HR P20201156 T1 HRP20201156 T1 HR P20201156T1 HR P20201156T T HRP20201156T T HR P20201156TT HR P20201156 T HRP20201156 T HR P20201156T HR P20201156 T1 HRP20201156 T1 HR P20201156T1
Authority
HR
Croatia
Prior art keywords
antigen
activates
binding
bispecific
cell
Prior art date
Application number
HRP20201156TT
Other languages
English (en)
Inventor
Christian Klein
Ekkehard Moessner
Ralf Hosse
Peter Bruenker
Pablo Umana
Christiane Jaeger
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20201156T1 publication Critical patent/HRP20201156T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/73—Expression systems using phage (lambda) regulatory sequences
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Claims (19)

1. Bispecifična molekula vezana na antigen koji aktivira T stanicu, naznačena time, da sadrži prvu i drugu funkcionalnu skupinu koja vezuje antigen, pri čemu prva funkcionalna skupina koja vezuje antigen sadrži prvi laki lanac i pri čemu je prva funkcionalna skupina koja vezuje antigen sposobna za specifično vezanje na antigen koji aktivira T stanicu, gdje je antigen koji aktivira T-stanicu CD3, dok druga funkcionalna skupina koja vezuje antigen sadrži drugi laki lanac i pri čemu je druga funkcionalna skupina koja vezuje antigen sposobna za specifično vezanje na antigen ciljne stanice, s time, da je antigen ciljne stanice receptor 1 folata (FolR1), pri čemu je aminokiselinska sekvenca prvog i drugog lakog lanca identična, gdje prvi i drugi laki lanac sadrže CDR-ove lakog lanca identifikacijskog broja sekvence: 32, identifikacijskog broja sekvence: 33 i identifikacijskog broja sekvence: 34, pri čemu je prva funkcionalna skupina koja vezuje antigen Fab i druga funkcionalna skupina koja vezuje antigen je Fab. 
2. Bispecifična molekula vezana na antigen koji aktivira T stanicu prema patentnom zahtjevu 1, naznačena time, da nadalje sadrži treću funkcionalnu skupinu koja vezuje antigen, sposobnu za specifično vezanje na antigen ciljne stanice. 
3. Bispecifična molekula vezana na antigen koji aktivira T stanicu prema patentnom zahtjevu 1, naznačena time, da nadalje sadrži Fc domenu sastavljenu od prve i druge podjedinice sposobne za stabilno udruživanje. 
4. Bispecifična molekula vezana na antigen koji aktivira T stanicu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time, da prvi i drugi laki lanac sadrže aminokiselinsku sekvencu identifikacijskog broja sekvence: 31. 
5. Bispecifična molekula vezana na antigen koji aktivira T stanicu prema patentnom zahtjevu 4, naznačena time, da prvi i drugi laki lanac sadrže aminokiselinsku sekvencu identifikacijskog broja sekvence: 35. 
6. Bispecifična molekula vezana na antigen koji aktivira T stanicu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačena time, da navedena funkcionalna skupina koja vezuje antigen, sposobna za specifično vezanje na antigen koji aktivira T stanicu, sadrži teški lanac koji sadrži CDR-ove teškog lanca identifikacijskog broja sekvence: 37, identifikacijskog broja sekvence: 38 i identifikacijskog broja sekvence: 39. 
7. Bispecifična molekula vezana na antigen koji aktivira T stanicu prema patentnom zahtjevu 2, naznačena time, da je prva, druga i treća funkcionalna skupina koja vezuje antigen svaka Fab molekula koja sadrži identičan laki lanac VLCL. 
8. Bispecifična molekula vezana na antigen koji aktivira T stanicu prema patentnom zahtjevu 2 ili 7, naznačena time, da je prva, druga i treća funkcionalna skupina koja vezuje antigen svaka Fab molekula koja sadrži CDR-ove lakog lanca identifikacijskog broja sekvence: 32, identifikacijskog broja sekvence: 33 i identifikacijskog broja sekvence: 34. 
9. Bispecifična molekula vezana na antigen koji aktivira T stanicu prema patentnom zahtjevu 2 ili 7, naznačena time, da je prva, druga i treća funkcionalna skupina koja vezuje antigen svaka Fab molekula koja sadrži laki lanac koji čini aminokiselinska sekvenca identifikacijskog broja sekvence: 31. 
10. Bispecifična molekula vezana na antigen koji aktivira T stanicu prema bilo kojem od patentnih zahtjeva 2 ili 7 do 9, naznačena time, da je svaka prva i treća funkcionalna skupina koja vezuje antigen na C-terminalnom kraju Fab teškog lanca spojena za N-terminalni kraj jedne od podjedinica Fc domene, a druga funkcionalna skupina koja vezuje antigen je na C-terminalnom kraju Fab teškog lanca spojena za N-terminalni kraj Fab teškog lanca prve funkcionalne skupine koja vezuje antigen. 
11. Bispecifična molekula vezana na antigen koji aktivira T stanicu prema bilo kojem od patentnih zahtjeva 3 do 10, naznačena time, da Fc domena je IgG, osobito IgG1 ili IgG4, Fc domena. 
12. Bispecifična molekula vezana na antigen koji aktivira T stanicu prema bilo kojem od patentnih zahtjeva 3 do 10, naznačena time, da Fc domena je ljudska Fc domena. 
13. Izolirani polinukleotid, naznačen time, da kodira bispecifičnu molekulu vezanu na antigen koji aktivira T stanicu prema bilo kojem od patentnih zahtjeva 1 do 12. 
14. Vektor, posebice vektor ekspresije, naznačen time, da sadrži izolirani polinukleotid prema patentnom zahtjevu 13. 
15. Stanica domaćina, naznačena time, da sadrži izolirani polinukleotid prema patentnom zahtjevu 13 ili vektor prema patentnom zahtjevu 14. 
16. Postupak proizvodnje bispecifične molekule vezane na antigen koji aktivira T stanicu prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time, da sadrži korake a) kultivacije stanice domaćina prema patentnom zahtjevu 15 u uvjetima prikladnima za ekspresiju bispecifične molekule vezane na antigen koji aktivira T stanicu i b) ponovnog dobivanja bispecifične molekule vezane na antigen koji aktivira T stanicu. 
17. Farmaceutski pripravak, naznačen time, da se sastoji od bispecifične molekule vezane na antigen koji aktivira T stanicu prema bilo kojem od patentnih zahtjeva 1 do 12 i farmaceutski prihvatljivog nosača. 
18. Bispecifična molekula vezana na antigen koji aktivira T stanicu prema bilo kojem od patentnih zahtjeva 1 do 12 ili farmaceutski pripravak prema patentnom zahtjevu 17, naznačeni time, da se primjenjuju kao medikament. 
19. Bispecifična molekula vezana na antigen koji aktivira T stanicu prema bilo kojem od patentnih zahtjeva 1 do 12 ili farmaceutski pripravak prema patentnom zahtjevu 17, naznačeni time, da su za primjenu u liječenju raka.
HRP20201156TT 2014-11-20 2020-07-23 Zajednički laki lanci i postupci primjene HRP20201156T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14194097 2014-11-20
PCT/EP2015/076745 WO2016079081A1 (en) 2014-11-20 2015-11-17 Common light chains and methods of use
EP15797972.5A EP3221357B1 (en) 2014-11-20 2015-11-17 Common light chains and methods of use

Publications (1)

Publication Number Publication Date
HRP20201156T1 true HRP20201156T1 (hr) 2020-11-13

Family

ID=51951675

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201156TT HRP20201156T1 (hr) 2014-11-20 2020-07-23 Zajednički laki lanci i postupci primjene

Country Status (20)

Country Link
US (3) US20170253670A1 (hr)
EP (2) EP3221357B1 (hr)
JP (2) JP7164949B2 (hr)
KR (1) KR20170087486A (hr)
CN (1) CN107207609B (hr)
BR (1) BR112017010513A2 (hr)
CA (1) CA2968162A1 (hr)
DK (1) DK3221357T3 (hr)
ES (1) ES2808853T3 (hr)
HK (1) HK1244011A1 (hr)
HR (1) HRP20201156T1 (hr)
HU (1) HUE049650T2 (hr)
LT (1) LT3221357T (hr)
MX (1) MX2017006626A (hr)
PL (1) PL3221357T3 (hr)
PT (1) PT3221357T (hr)
RS (1) RS60615B1 (hr)
RU (1) RU2747011C2 (hr)
SI (1) SI3221357T1 (hr)
WO (1) WO2016079081A1 (hr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
ES2549638T3 (es) 2011-02-28 2015-10-30 F. Hoffmann-La Roche Ag Proteínas de unión a antígeno
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
KR101870555B1 (ko) 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
WO2014056783A1 (en) 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
RU2015140915A (ru) 2013-02-26 2017-04-03 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
MY192312A (en) 2013-02-26 2022-08-17 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
MX2016003593A (es) * 2013-10-11 2016-06-02 Hoffmann La Roche Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
PE20170263A1 (es) 2014-08-04 2017-03-30 Hoffmann La Roche Moleculas biespecificas de union a antigeno activadoras de celulas t
BR112017010324A2 (pt) 2014-11-20 2018-05-15 F. Hoffmann-La Roche Ag método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CN107849137B (zh) 2015-10-02 2021-11-26 豪夫迈·罗氏有限公司 双特异性抗ceaxcd3 t细胞活化性抗原结合分子
JP7325186B2 (ja) 2015-12-09 2023-08-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗薬物抗体の形成を減少させるためのｉｉ型抗ｃｄ２０抗体
MX2018008347A (es) 2016-01-08 2018-12-06 Hoffmann La Roche Metodos de tratamiento de canceres positivos para ace utilizando antagonistas de union a eje pd-1 y anticuerpos biespecificos anti-ace/anti-cd3.
CU24613B1 (es) 2016-02-06 2022-07-08 Epimab Biotherapeutics Inc Proteínas de unión a inmunoglobulinas fabs en tandem (fit-ig) biespecíficas que se unen a cmet y egfr
CN108778329B (zh) 2016-02-17 2022-09-16 西雅图基因公司 Bcma抗体和其用以治疗癌症和免疫病症的用途
CN109153728A (zh) 2016-03-21 2019-01-04 埃尔斯塔治疗公司 多特异性和多功能分子及其用途
FI3433280T3 (fi) 2016-03-22 2023-06-06 Hoffmann La Roche Proteaasin aktivoimia t-solubispesifisiä molekyylejä
SG11201808085WA (en) * 2016-03-22 2018-10-30 Hoffmann La Roche Protease-activated t cell bispecific molecules
AU2017281034B2 (en) * 2016-06-21 2024-03-14 Teneobio, Inc. CD3 binding antibodies
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3500301B1 (en) * 2016-08-16 2023-08-30 Epimab Biotherapeutics Inc. Monovalent asymmetric tandem fab bispecific antibodies
WO2018052503A1 (en) 2016-09-14 2018-03-22 Teneobio, Inc. Cd3 binding antibodies
EP3519437B1 (en) 2016-09-30 2021-09-08 F. Hoffmann-La Roche AG Bispecific antibodies against p95her2
IL302917A (en) 2016-10-07 2023-07-01 Tcr2 Therapeutics Inc Preparations and methods for reprogramming T-cell receptors using fusion proteins
EP3544996A2 (en) 2016-11-22 2019-10-02 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
AU2018221731C1 (en) 2017-02-17 2021-11-18 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
AU2018288803A1 (en) 2017-06-20 2020-02-06 Teneoone, Inc. Anti-BCMA heavy chain-only antibodies
AU2018393076A1 (en) 2017-12-19 2020-07-02 Surrozen Operating, Inc. Anti-LRP5/6 antibodies and methods of use
JP7330977B2 (ja) 2017-12-19 2023-08-22 スロゼン オペレーティング， インコーポレイテッド Ｗｎｔサロゲート分子及びその使用
SG11202005880XA (en) 2017-12-22 2020-07-29 Teneobio Inc Heavy chain antibodies binding to cd22
AU2019218959A1 (en) 2018-02-08 2020-09-03 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20210009711A1 (en) 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
CN112384243A (zh) * 2018-04-17 2021-02-19 英温拉公司 三价三特异性抗体构建体
KR102480493B1 (ko) * 2018-06-08 2022-12-21 크리스탈 바이오사이언스 주식회사 동일한 경쇄 i을 갖는 다양한 항체를 생산하기 위한 트랜스제닉 동물
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
MX2021000488A (es) 2018-07-19 2021-04-12 Regeneron Pharma Anticuerpos anti-bcma x anti-cd3 biespecificos y usos de estos.
WO2020132356A1 (en) * 2018-12-19 2020-06-25 Surrozen, Inc. Antigen binding formats for receptor complexes
WO2020172571A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN114127111A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
AU2020226904A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
SG11202109056TA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
SG11202109033XA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
JP2022537931A (ja) 2019-06-14 2022-08-31 テネオバイオ， インコーポレイテッド Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
CN110229232B (zh) * 2019-06-19 2020-05-19 北京智仁美博生物科技有限公司 双特异性抗体及其用途
CN110551222B (zh) * 2019-08-27 2023-06-06 重庆市畜牧科学院 一种新型双功能抗体及其用途
CN114981297A (zh) 2019-12-23 2022-08-30 戴纳立制药公司 颗粒蛋白前体变体
CN110982839A (zh) * 2019-12-25 2020-04-10 上海药明生物技术有限公司 对蛋白在细胞水平进行生物素标记的方法
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
JP2023523011A (ja) 2020-04-24 2023-06-01 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
BR112022021690A2 (pt) 2020-04-29 2022-12-20 Teneobio Inc Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
AU2021291011A1 (en) 2020-06-19 2023-01-05 F. Hoffmann-La Roche Ag Antibodies binding to CD3 and CD19
AU2021300362A1 (en) 2020-07-01 2023-02-23 ARS Pharmaceuticals, Inc. Anti-ASGR1 antibody conjugates and uses thereof
CN116761818A (zh) 2020-08-26 2023-09-15 马伦戈治疗公司 检测trbc1或trbc2的方法
GB2616128A (en) 2020-08-26 2023-08-30 Marengo Therapeutics Inc Antibody molecules that bind to NKp30 and uses thereof
CN116249718A (zh) 2020-08-26 2023-06-09 马伦戈治疗公司 结合至钙网蛋白的多功能性分子及其用途
BR112023020832A2 (pt) 2021-04-08 2023-12-19 Marengo Therapeutics Inc Moléculas multifuncionais ligadas a tcr e seus usos

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2388385B1 (fr) 1977-04-18 1982-01-08 Hitachi Metals Ltd Piece d'ornement fixee par des aimants permanents
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE69830901T2 (de) * 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
NZ556286A (en) 2005-02-07 2010-11-26 Glycart Biotechnology Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
LT2520590T (lt) 2007-04-03 2018-09-10 Amgen Research (Munich) Gmbh Susijusioms rūšims specifinis rišantis domenas
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
US20130045492A1 (en) * 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SI2748202T1 (sl) * 2011-08-23 2018-10-30 Roche Glycart Ag Bispecifične molekule, ki se vežejo na antigen
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
SG10201609535TA (en) * 2012-06-05 2017-01-27 Regeneron Pharma Methods for making fully human bispecific antibodies using a common light chain
SI2900694T1 (sl) * 2012-09-27 2018-12-31 Merus N.V. Bispecifična IGG protitelesa kot vključitelji T-celic
WO2014056783A1 (en) * 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
US10968276B2 (en) * 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
MY192312A (en) * 2013-02-26 2022-08-17 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
EP3424952A1 (en) * 2013-03-15 2019-01-09 Amgen, Inc Heterodimeric bispecific antibodies

Also Published As

Publication number Publication date
US20200172633A1 (en) 2020-06-04
JP2018504092A (ja) 2018-02-15
EP3747905A1 (en) 2020-12-09
RS60615B1 (sr) 2020-08-31
KR20170087486A (ko) 2017-07-28
PT3221357T (pt) 2020-07-28
RU2017121326A3 (hr) 2019-06-14
BR112017010513A2 (pt) 2018-04-03
RU2747011C2 (ru) 2021-04-23
US20220213224A1 (en) 2022-07-07
EP3221357A1 (en) 2017-09-27
JP2021129564A (ja) 2021-09-09
LT3221357T (lt) 2020-08-25
HK1244011A1 (zh) 2018-07-27
MX2017006626A (es) 2017-08-21
JP7164949B2 (ja) 2022-11-02
CN107207609A (zh) 2017-09-26
PL3221357T3 (pl) 2020-11-02
EP3221357B1 (en) 2020-06-03
RU2017121326A (ru) 2018-12-20
CA2968162A1 (en) 2016-05-26
ES2808853T3 (es) 2021-03-02
WO2016079081A1 (en) 2016-05-26
US20170253670A1 (en) 2017-09-07
HUE049650T2 (hu) 2020-11-30
CN107207609B (zh) 2022-07-19
DK3221357T3 (da) 2020-08-10
SI3221357T1 (sl) 2020-09-30

Similar Documents

Publication Publication Date Title
HRP20201156T1 (hr) Zajednički laki lanci i postupci primjene
HRP20201747T1 (hr) Bispecifične antigen vezujuće molekule koje aktiviraju t stanice, protiv folr1 i cd3
HRP20191704T1 (hr) Multispecifična protutijela
HRP20192098T1 (hr) Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene
HRP20200572T1 (hr) Anti-pvrig antitijela i postupci uporabe
CO2018013500A2 (es) Anticuerpos anti-pd-l1 y usos de los mismos
HRP20230060T1 (hr) Antitijela protiv ox40 i njihova primjena
HRP20210739T1 (hr) Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada
HRP20202024T1 (hr) Cd3-vežuća domena
HRP20211794T1 (hr) Humana antitijela za pd-1
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
HRP20231579T1 (hr) Anti-ctla-4 antitijela i postupci njihove upotrebe
CL2019003000A1 (es) Proteínas de unión a antígenos trem2 y usos de estas.
EP4282877A3 (en) Chimeric antigen receptors targeting bcma and methods of use thereof
FI3515487T3 (fi) Bispesifisiä anti-MUC16-CD3-vasta-aineita ja anti-MUC16-lääkekonjugaatteja
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
RU2018107802A (ru) Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин
PE20190976A1 (es) Anticuerpos de union a cd3
PE20240111A1 (es) Moleculas de union a pd-1 y metodos de uso de las mismas
RU2016129517A (ru) Биспецифические антитела к her2 и способы применения
HRP20230237T1 (hr) Anti-psma antitijela, bispecifične molekule za vezanje antigena koje vežu psma i cd3, i njihova uporaba
BR112017019978A2 (pt) anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
AR101829A1 (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1